The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ (Euronext & Nasdaq: ARGX) Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo ...
A biotech company developing bispecific antibodies for immunological and inflammatory (I&I) disorders. Bambusa Therapeutics was founded in May 2024 and has two lead programs: BBT001 and BBT002, which ...
Positive top-line results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of Cobenfy (xanomeline and trospium chloride) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results